InvestSMART

Cryosite Limited (ASX:CTE)

ALERT: Price-sensitive ASX Announcement for CTE
Current share price for CTE : $1.250 0.18 (16.82%)+
Announcement
Release
27 May 2026 8:53AM
Price at Release
$1.070
Full Release
download
Summary
Cryosite Limited reported strong financial performance for the ten months ending 30 April 2026. Revenue increased by 22% and EBITDA by 28%, supported by increased infrastructure utilization and global clinical trial activity. The company expanded its operational capabilities with new infrastructure and strengthened its balance sheet by refinancing its debt facility. Cryosite participated in the R&D Tax Incentive program and achieved EcoVadis Gold Medal status for sustainability. It continues to manage supply chain pressures and cost reduction strategies, and is well-positioned to capitalize on growth opportunities in the global life sciences sector.
Key Points
  • Revenue increased by 22% to $13.8 million.
  • EBITDA increased by 28% to $3.4 million.
  • Cryosite completed infrastructure expansion at Ferndell Street.
  • The Adderley Street warehouse is under commissioning.
  • Refinanced debt facility with NAB until 2030.
  • Achieved EcoVadis Gold Medal status for sustainability.
  • Participated in the R&D Tax Incentive program.
  • Operational volumes indicate continuing positive momentum.
  • Cryosite focuses on growth in Ultra-Frozen & Cryogenic segment.
  • Continues to manage cost pressures effectively.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.